Azenta (AZTA) is a provider of life sciences worldwide, enabling therapies to market faster. George Tsilis discusses AZTA as its trading higher after better-than-expected 4Q earnings. He talks about how AZTA announced a $1.5B share-repurchase program. He notes that the company's 4Q revenue came in at $138.00M versus an estimated $133.72M. He then goes over how AZTA works in areas such as drug development, clinical research, and advanced cell therapies. Tune in to find out more about the stock market today.
15 Nov 2022
Trading 360
13 Oct 2023
Market On Close
26 Oct 2023
Fast Market
09 Nov 2023
Trading 360
11 Oct 2023
The Watch List
18 Aug 2023
Next Gen Investing
01 Sep 2023